Combination therapy (temozolomide and α-IFN) for...

Details Combination therapy (temozolomide and α-IFN) for... Combination therapy (temozolomide and α-IFN) for...

2007-11-13

2007-11-13

Saoud, Christine J. (Department: 1647)

Drug, bio-affecting and body treating compositions

Lymphokine

Interferon

C424S085400

Reexamination Certificate

active

10134183

ABSTRACT:
There is disclosed a method for treating advanced cancer in patients in need of such treating. Temozolomide and alpha interferon are administered in combination in amounts sufficient to achieve a clinical response.

REFERENCES:
patent: 5242909 (1993-09-01), Teelmann
patent: 5503828 (1996-04-01), Testa et al.
patent: 5610220 (1997-03-01), Klimmek et al.
patent: 5824346 (1998-10-01), Dugan
patent: WO 89/06139 (1989-07-01), None
patent: WO 90/06135 (1990-06-01), None
Wadlet et al. Biological agents as biochemical modulators:pharmacological basis for the interaction of cytotoxic chemotherapeutic drugs and interferon (1994). Cancer Chemother. Pharmacol. vol. 35, pp. 21-30.
Bleehen et al. Cancer Research Campaign Phase II Trial of Temozolomide in Metastatic Melanoma (1995). J. Clin. Oncology. vol. 13 pp. 910-913.
Newlands et al. Phase I trial of temozolomide (CCRG81045: M7B 39831: NSC362856) (1992). Br. J. Cancer, vol. 65, pp. 287-291.
Sparano et al. Clinical and Pharmacological studies of interferon and chemotherapy in gastrointestinal and breast cancer (1993). Int. J. Cli. Pharm. Res. vol. 13 pp. 1-9.
Atkins M.B. et al., “Phase II Pilot Trial of Concurrent Biochemotherapy with Cisplatin, Vinblastine, Temozolomide (CVT), Interleukin-2 (IL-2) and Interferon alpha-2b (IFN) in Patients with Metastatic Melanoma”, Meeting Abstract of Proc. Annu. Meet. Am. Soc. Clin. Oncol, 2001:1391.
Tsioulias G.J. et al., “Salvage metastasectomy improves survival in stage IV Melanoma Patients treated with concurrent biochemotherapy”, Meeting Abstract of Proc. Annu. Meet. Am. Soc. Clin. Oncol, 2001:1440.
Gibbs P. et al., “A multicenter phase II study of modified biochemotherapy (BCT) for stage IV melanoma incorporating temozolomide, decrescendo interleukin-2 (IL-2) and GM-CSF”, Meeting Abstract of Proc. Annu. Meet. Am. Soc. Clin. Oncol, 2000;19:A2255.
Gonzalez R. et al., “A preliminary analysis of a multicenter phase II study of biochemotherapy with temozolomide, cisplatin, interleukin-2, alpha-interferon, and granulocyte macrophage colony stimulating factor (GM-CSF) for stage IV melanoma”, Meeting Abstract of Chemotherapy Foundation Symposium XVII. 11/3-6/99.Cancer Invest., 2000;18 (Suppl. 1): Abstract 78.
Kersen M-J. et al., “Combined immunotherapy with Gm-CSF, IL-2 and IFN? Allows dose escalation of temozolomide with prevention of lymphocytopenia and brain metastases in metastatic malignant melanoma”, Meeting Abstract of Proc. Annu. Meet. Am. Soc. Clin. Oncol, 2000;19:A2244.
Kirkwood J.M. et al., “Phase I study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma”, Meeting Abstract of Proc. Annu. Meet. Am. Soc. Clin. Oncol, 1997;16:A1767.
Ruggero R. et al., “TMZ plus IFN-2 alpha in metastatic melanoma; preliminary evaluation of a multicenter phase II study of the Italian Melanoma Intergroup”, Am. Soc. Clin. Oncol. 2002, Abstract No. 1388.
Danson S. et al., “A randomized study of temozolomide (TMZ) alone, with interferon (TMZ-IFN) or with thalidomide (TMZ-THAL) in metastatic malignant melanoma (MMM)”, Am. Soc. Clin. Oncol. 2002, Abstract No. 1369.
Garcia Martin M. et al., “Phase II multicenter study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma”, Am. Soc. Clin. Oncol. 2002, Abstract No. 1389.
Weber R. et al., “A phase II trial of Temozolomide, GM-CSF, IFN-2 alpha, IL-2 in patients with metastatic melanoma”, Am. Soc. Clin. Oncol. 2002, Abstract No. 2791.
Physicians'Desk Reference, Electronic Edition 2002, PDR Entry for Temoar (Temozolomide).
Goodman and Gilman'sThe Pharmacological Basis of Therapeutics, Eighth Edition, pp. 1205-1207 (1990).
Ridolfi, R. et al., “TMZ plus IFN-2 alpha in metastatic melanoma; preilminary evaluation of a multicenlar phase II study of the Italian Melanoma Intergroup”, Am. Soc. Clin. Oncol. 2002, Abstract No. 1388.
Yung, W.K.A. et al., “A combination of temozolomide and interferon-A in recurrent malignant gllomas, a phase II study”, Fourth Annual Meeting of the Society for Neuro-Oncology, Nov. 17-21, 1999, Scottsdale, Arizona; Neuro-Oncology, Oct. 1999, 293-294.
Abrams et al., “New Chemotherapeutic agents for breast cancer,”Cancer, 74(3 Suppl.): 1164-1176 (1994).
Carter et al., “Responses of human melanoma, ovarian, and colon tumor xenografts nude mice to oral temozolomide,” Proc Annu Meet Am Assoc Cancer Res, 35:297, Abstract 1769 (1994).

Affiliated with

Also associated with

Rating

Combination therapy (temozolomide and α-IFN) for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination therapy (temozolomide and α-IFN) for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy (temozolomide and α-IFN) for... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3854185